(Reuters) -The U.S. Food and Drug Administration approved Soleno Therapeutics’ drug to treat a rare genetic disorder on Wednesday, making it the first treatment available for patients who experience feelings of intense and persistent hunger. Shares of the company were halted for trading. The drug, branded as Vykat XR, received FDA’s approval to treat Prader-Willi syndrome, a genetic disorder